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httpcense.Abstract Introduction: Obesity and asthma prevalence have been increasing over the past decade.
Osteopontin (OPN) is a cytokine, with suggested diverse roles in tissue remodeling, ﬁbrosis, immu-
nomodulation, inﬂammation, and tumor metastasis.
Aim of the work: To assess the relation between serum osteopontin, immunoglobulin E (IgE) and
body fat percentage in obese and non-obese asthmatic women in addition, to determine whether
correlations exist between these parameters and asthma control.
Patients and methods: This study was conducted on 40 women after taking informed written
consents. They were divided into 4 groups (10 each): healthy non-obese non-asthmatic (NO/NA),
obese non-asthmatic (O/NA), non-obese asthmatic (NO/A) and obese asthmatic (O/A). All were
subjected to full history taking, spirometry to non-asthmatic, asthma control questionnaire
(ACQ) to asthmatic, determination of body fat percentage and serum levels of osteopontin and IgE.
Results: Body fat percentage was positively correlated to serum OPN levels. Body fat percentage
was positively correlated to concentrations of IgE. In addition, the correlation between serum OPN
levels and serum IgE levels was signiﬁcantly positive. The improvement (presented by difference
between ACQ before and after treatment (D ACQ)) was signiﬁcantly superior in non-obese asth-
matic. A negative correlation was detected between D ACQ and body fat percentage, serum
OPN and IgE concentration.24474317.
.com (E.E. Mohamed).
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88 E.E. Mohamed et al.In conclusion: Because the multiple roles of OPN action potentially contribute to inﬂammation
in obesity, it is suggested that, in addition to weight reduction, interference with OPN action could
become a therapeutic strategy in the treatment of obesity worsening disorders like bronchial
asthma.
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Asthma is characterized by eosinophilic inﬂammation of
the conducting airways, and is regarded as a typical type-2
T-helper cell (Th2) associated allergic disease [1]. Airway
inﬂammation in asthma is a multicellular process that is asso-
ciated with structural alterations of the airway components, a
process known as airway remodeling. The prominent role of
airway inﬂammation and remodeling in the pathogenesis and
clinical presentation of asthma has led to the current focus
on mediators potentially involved in both processes [2].
Obesity and asthma prevalence have been increasing over
the past decade. Several studies have identiﬁed an association
between obesity and asthma and demonstrated that obesity
results in an increased risk of developing bronchial asthma.
Even modest levels of increased weight increase asthma risk.
Moreover, obese asthmatic patients demonstrate increased
asthma severity, as indicated by increased exacerbations and
worse asthma control [3–5]. Most of these studies restricted
their measurement of excess body weight to body mass index
(BMI); however, other measures, such as total body fat or
body fat percentage are more precise in order to determine
the relative importance of obesity in the pathophysiology of
bronchial asthma. It has been suggested that the association
between obesity and asthma prevalence is stronger in women
than men. A cross-sectional study found that a one-unit in-
crease of BMI was associated with a 6% increase in asthma
risk in women and 3% increase in men [6].
Published data suggest that obese asthma patients may rep-
resent a distinct phenotype of asthma [7,8]. Obese asthma
patients demonstrate increased asthma severity, as indicated
by increased exacerbations and decreased responses to conven-
tional asthma therapies, speciﬁcally, relative corticosteroid
resistance [9]. Small studies suggest improvements in the dis-
ease with weight loss in obese asthma patients. It is possible
that altered lung mechanics associated with obesity could
increase severity and worsen asthma control [10]. However,
it is unclear and controversial whether the effects of obesity
on asthma are mechanically mediated through restrictive
effects on chest wall expansion or mediated through other
mechanisms that are speciﬁc to the obese state. These sug-
gested mechanisms include: (1) the presence of co morbidities,
such as gastroesophageal reﬂux disease and sleep disordered
breathing, (2) systemic and/or airway inﬂammation associated
with obesity (with elevated levels of circulating inﬂammatory
cytokines, such as interleukin-6 (IL-6) and tumor necrosis fac-
tor-a (TNF-a), and (3) increased oxidative stress in obesity [8].
Multiple studies investigated the relationship between serum
levels of hormones related to adipose tissue, such as adiponectin,
leptin, and resistin and bronchial asthma. Although the data are
sometimes conﬂicting, it seems that these adipocytokines may
modulate airway inﬂammation and bronchial hyperreactivity.However, the relationship between serum levels of leptin/adipo-
nectin and the presence of asthma is not sufﬁcient to explain the
relationship between asthma and obesity [11,12].
Osteopontin (OPN) is a cytokine, with suggested diverse
roles in tissue remodeling, ﬁbrosis, immunomodulation,
inﬂammation, and tumor metastasis. It was originally
described as a structural component of the extracellular matrix
having the ability to bind to proteins and most types of colla-
gen [13]. Although OPN is synthesized at the highest levels in
the bone, it is produced by most cells of the immune system,
including T-cells, B-cells, macrophages, neutrophils, eosino-
phils, natural killer cells and mast cells, as well as structural
cells, including ﬁbroblasts and smooth muscle and epithelial
cells. In humans, increased OPN expression has been observed
in a number of type-1 T-helper cells (Th1)-mediated lung dis-
eases, including granulomatous diseases and pulmonary ﬁbro-
sis [14]. There is now, also, emerging evidence to support an
active role for OPN in type-2 T-helper cell (Th2)-linked inﬂam-
mation and remodeling. OPN expression is upregulated in
nasal tissue samples taken from asthmatic patients with
chronic rhinosinusitis, and in the tear ﬂuids of patients with
allergic ocular diseases [15,16]. It has previously been demon-
strated that OPN plays a crucial role in allergic airway inﬂam-
mation [17–19]. Endobronchial biopsies from asthmatic
individuals have shown increased osteopontin expression in
bronchial epithelial cells and subepithelial inﬂammatory cells
suggesting that eosinophils may be a cellular source of OPN
[20]. Moreover, OPN is expressed in peripheral blood eosino-
phils of atopic human subjects, and acts as a chemoattractant
for eosinophils in vitro [17,18]. It also may participate in the
regulation of serum immunoglobulin E (IgE) levels in both
asthmatic and non-asthmatic subjects [20].
Experimental studies on murine animal models of allergic
airway disease demonstrated that OPN levels are increased
in allergen-induced chronic airway remodeling, whereas, oste-
opontin deﬁciency, either through administration of blocking
antibody or genetic deﬁciency, is protective against airway hy-
per-responsiveness (AHR) and airway remodeling [21,22].
Go´mez-Ambrosi and his co-workers found that, plasma
OPN levels and OPN expression in omental adipose tissue
are increased in obese patients with high values of body fat
percentage. It was suggested that measurement of OPN might
be useful for evaluating the outcomes of obesity-related cardio-
vascular diseases [23].
Aim of the work
The aim of this study was to assess the relation between serum
osteopontin, IgE levels and body fat percentage in obese and
non-obese asthmatic women in addition, to determine whether
correlations exist between these parameters and asthma con-
trol in these patients.
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After approval of the Ethics Committee of the Faculty of Med-
icine, Alexandria University, this study was conducted on 40
women, non-smokers, whose ages ranged between 20 and
40 years without co-morbidities that could potentially interfere
with the study or other pulmonary diseases. Informed and
written consents were obtained from all participating subjects.
All asthmatic patients were recruited from the inpatients of
Chest Diseases Department, Alexandria Main University Hos-
pital. The study population were divided into 4 groups (10
each): healthy non-obese non-asthmatic women (NO/NA), ob-
ese non-asthmatic women (O/NA), non-obese asthmatic
women (NO/A) and obese asthmatic women (O/A).
All subjects were subjected to the following
 Full history taking including: age and history of other
diseases.
 Thorough clinical examination including: general examina-
tion and local chest examination.
 Spirometry, all non-asthmatic women underwent standard
spirometry. Techniques were carried out according to the
American Thoracic Society/European Respiratory Society
standards [24].
 Asthma control was assessed using the asthma control
questionnaire (ACQ) [25]. It was applied to asthmatic obese
and non-obese groups at the onset of hospital admission
and after 2 weeks of treatment. Brieﬂy, ACQ comprises of
seven items; the patient completes six. The items quantify
the extent of ﬁve symptom measures: nighttime awakenings,
symptom severity upon awakening, activity limitation due
to asthma, and shortness of breath due to asthma and
wheezing within the past week, each rated on a 7-point
scale, where 0 represents no symptoms or limitations, and
6 indicates severe symptoms or impairment. The sixth
patient-reported item counts the past week’s use of a short
acting b-agonist (SABA), where 0 represents ‘‘None’’ and 6
represents ‘‘More than 16 puffs most days.’’ The seventh
item is the clinician-assessed FEV1 percentage predicted
scored using a 7-point scale, where 0 represents ‘‘>95%
predicted’’ and 6 represents ‘‘<50% predicted’’. The over-
all score is the mean of the item responses and ranges from
0 (totally controlled) to 6 (severely uncontrolled). Scores
below 1 represents well controlled asthma and scores above
1.5 indicates poorly controlled asthma.
 Determination of body fat percentage was performed by
bioelectric impedance using Inbody-220 (Biospace, South
Korea, 2005). The analysis was done under standardized
conditions: after 8 h of fasting, no intense physical exercise
in the previous 12 h, and absence of menstrual cycle 2 days
before and after testing. According to Gallagher et al.’s
results, adult females with body fat percentage between
21% and <33% were considered healthy, and those with
body fat percentage P33 were considered obese [26].
 Under complete sterile conditions, ﬁve-milliliters of venous
blood were withdrawn from every participant. Every sam-
ple was transferred into a disposable plastic tube and left
to coagulate at room temperature for 10–20 min then cen-
trifuged for 20 min at the speed of 5000 r.p.m. to separate
the serum. The sera were stored in aliquots at 20 C until
measurement of osteopontin and IgE.Estimation of serum osteopontin (OPN) level by ELISA
technique
The commercial kit used was WKEAMED SUPPLIES CORP
USA Address: 450 11TH AVE, NEW YORK, NY 10123.
Brieﬂy, standards and samples were pipetted into the wells
and OPN present in a sample was bound to the wells by the
immobilized antibody. The wells were washed and biotinylated
anti-human OPN antibody was added. After washing away
unbound biotinylated antibody, horseradish peroxidase
(HRP)-conjugated streptavidin was pipetted to the wells. The
wells were again washed; a tetramethyl-benzidine (TMB) sub-
strate solution was added to the wells and color developed in
proportion to the amount of OPN bound. The Stop Solution
changed the color from blue to yellow, and the intensity of
the color was measured at 450 nm. Assay range was from 2
to 40 lg/L, Intra-Assay and Inter-Assay coefﬁcients of varia-
tion were CV < 10% and CV< 12%, respectively.
Estimation of IgE concentration by ELISA technique
ImmunoSpec IgE Quantitative Enzyme Immunoassay for total
serum IgE was provided from IMMUNOSPEC CORPORA-
TION 7018 Owens mouth Ave. Suite 103 Canoga Park, CA,
91303. Brieﬂy, immunoSpec IgE Quantitative Test Kit was
based on a solid phase enzyme-linked immunosorbent assay.
The serum samples and standards were added to the IgE anti-
body coated microtiter wells and incubated with Zero Buffer.
The wells were then washed to remove any residual test speci-
men, and then IgE antibody labeled with horseradish peroxi-
dase (conjugate) was added. After incubation at room
temperature, the wells were washed with water to remove
unbound labeled antibodies. A solution of TMB was added
and incubated for 20 min, resulting in the development of a
blue color. The color development was stopped with the addi-
tion of the Stop Solution, and the color was changed to yellow
and measured spectrophotometrically at 450 nm. The minimal
sensitivity of this assay is about 5.0 IU/ml.
Statistical analysis
Data are presented as mean ± SD. Comparisons between
groups regarding each variable were analyzed by one-way
Analysis of Variances ANOVA followed by Multiple/Post
Hoc Group Comparisons test using least signiﬁcant difference
procedure for computing the differences between the four groups.
Unpaired t-tests for comparing ACQ scores between asthmatic
groups and spirometric ﬁndings between non-asthmatic
groups, and by paired t-tests for assessment of treatment effect
on the ACQ. Correlations between variables were computed
by Pearson’s correlation coefﬁcients (r). Statistical analysis
was performed with Statistical Toolbox for the MATLAB
(Matrices Laboratory software version R2008b). P value lower
than 0.05, was considered statistically signiﬁcant.
Results
Body fat percentage, serum OPN levels and IgE concentrations
In this study, as expected, the body fat percentage was
signiﬁcantly higher (P< 0.0001) in obese asthmatics and
Table 1 Body fat percentage, serum osteopontin levels (in lg/L) and IgE concentrations (in IU/mL).
Parameters Non-obese
non-asthmatic
Obese
non-asthmatic
Non-obese
asthmatic
Obese asthmatic F (P)
Body fat % 29.260 ± 2.605
(23.5–32.0)
46.840 ± 5.157*
(38.0–53.6)
29.650 ± 1.696#
(26.5–31.7)
49.950 ± 4.557*h
(40.8–54.8)
85.014912 (P< 0.0001)
Serum osteopontin levels (lg/L) 37.900 ± 3.771
(33.1–45.5)
56.910 ± 7.465*
(43.5–65.8)
60.160 ± 8.159*
(47.9–71.3)
84.620 ± 8.246*#h
(70.7–96.4)
71.981007 (P< 0.0001)
Serum IgE levels (Iu/mL) 12.510 ± 2.669
(8.3–16.3)
24.870 ± 9.130
(8.1–38.5)
589.030 ± 72.158*#
(481.1–730.3)
799.050 ± 60.749*#h
(683.4–899.6)
709.458665 (P< 0.0001)
Data are presented as mean ± sd (minimum–maximum). Differences between groups were analyzed by ANOVA followed by least signiﬁcant
difference tests.
* Signiﬁcant from non obese-non asthmatic group P< 0.0001.
# Signiﬁcant from obese non asthmatic group P< 0.0001.
h Signiﬁcant from non obese asthmatic group P< 0.0001.
Figure 1 Comparison of body fat percentage in the different
groups.
Figure 2 Comparison of serum OPN concentrations in the
different groups.
90 E.E. Mohamed et al.non-asthmatics (49.950 ± 4.557% and 46.840 ± 5.157%,
respectively) as compared to non-obese asthmatics and
non-asthmatics (29.650 ± 1.696% and 29.260 ± 2.605%,
respectively). As regards serum OPN levels, the highest values
were observed in the obese asthmatic (84.620 ± 8.246 lg/L)
while the lowest in the non-obese non-asthmatic patients
(37.900 ± 3.771 lg/L) with a signiﬁcant difference (P<
0.0001), however, no signiﬁcant difference between obese
non-asthmatic (56.910 ± 7.465 lg/L) and asthmatic non-obese
(60.160 ± 8.159 lg/L) patients was detected (P= 0.31625).
Increased concentrations of IgE (P< 0.0001) were observed
only in the asthmatic groups but it was signiﬁcantly higher
(P< 0.0001) in the obese (799.050 ± 60.749 Iu/mL) than in
the non-obese (589.030 ± 72.158 Iu/mL) patients (Table 1
and Figs. 1–3).
The present study conveyed that body fat percentage was
positively correlated to serum OPN levels (r= 0.940728;
P< 0.0001 in non-asthmatic groups and r= 0.92191;
P< 0.0001 in asthmatic groups) and to the concentrations
of IgE (r= 0.818011; P< 0.0001 in non-asthmatic groups
and r= 0.83522; P< 0.0001 in asthmatic groups). Again,
the correlation between serum OPN levels and serum IgE lev-
els was signiﬁcantly positive (r= 0.857439; P< 0.0001 in
non-asthmatics and r= 0.77018; P< 0.0001 in asthmatics).
(Tables 3 and 4 and Figs. 4–6).Spirometric ﬁndings for non-asthmatic women
By comparing spirometric results (Table 2) in non-asthmatic
women; it was observed that the percentage of predicted of
forced vital capacity (FVC) (P< 0.0001), forced expiratory
volume after the ﬁrst second (FEV1) (P< 0.0001) and maxi-
mum voluntary ventilation (MVV) (P= 0.0002) were signiﬁ-
cantly higher in the healthy non-obese-non asthmatic women
(93.200 ± 4.517, 92.600 ± 5.522 and 98.300 ± 5.618, respec-
tively) as compared to the obese-non asthmatic women
(77.400 ± 3.340, 84.300 ± 2.669 and 77.000 ± 5.055, respec-
tively). However forced expiratory volume after the ﬁrst sec-
ond/forced vital capacity (FEV1/FVC) ratio showed no
statistical signiﬁcant difference (P= 0.3867) between the two
groups (87.100 ± 2.279 vs 86.820 ± 1.995). These ﬁndings
indicate that obesity has some restrictive effect on pulmonary
functions.
In the current work, we demonstrated a signiﬁcant negative
correlation that was found between the body fat percentage
and the percentage of predicted of FVC (r= 0.894877;
P< 0.0001), FEV1 (r= 0.704924; P= 0.0005) and MVV
(r= 0.930590; P< 0.0001). Furthermore, the percentage
of predicted of FVC, FEV1 and MVV were negatively corre-
lated to serum OPN levels (r= 0.791279; P< 0.0001,
r= 0.593556; P= 0.0058 and r= 0.923399; P< 0.0001,
respectively) (Table 3).
Figure 3 Comparison of serum IgE levels in the different groups.
Table 2 Spirometric ﬁndings for non-asthmatic women.
Parameters Non-obese non-asthmatic Obese non-asthmatic t (P)
FVC 93.200 ± 4.517
(88.000–102.000)
77.400 ± 3.340
(71.000–83.000)
8.894451507
(P< 0.0001)*
FEV1 92.600 ± 5.522
(84.000–104.000)
84.300 ± 2.669
(80.000–88.000)
4.279765866
(P= 0.0002)*
FEV1/FVC ratio 87.100 ± 2.279
(82.900–89.700)
86.820 ± 1.995
(83.300–89.300)
0.292280457
(P= 0.38671)
MVV 98.300 ± 5.618
(94.000–109.000)
77.000 ± 5.055
(70.000–84.000)
8.912038546
(P< 0.0001)*
Data are presented as mean ± sd (minimum–maximum).
Differences between groups were analyzed by unpaired t test. FVC: forced vital capacity, FEV1: forced expiratory volume after the ﬁrst second,
FEV1/FVC: forced expiratory volume after the ﬁrst second/ forced vital capacity and MVV: maximum voluntary ventilation.
* Signiﬁcant from the non-obese non-asthmatic group.
Table 3 The correlations between different parameters studied in non-asthmatic groups.
Parameters studied Body fat
percentage
Serum osteopontin
level (lg/L)
Serum IgE
levels (Iu/mL)
FVC FEV1 FEV1/FVC ratio
Serum osteopontin levels (lg/L) r 0.940728
p <0.0001*
Serum IgE levels (Iu/mL) r 0.818011 0.857439
p <0.0001* <0.0001*
FVC r 0.894877 0.791279 0.632872
p <0.0001* <0.0001* 0.0027*
FEV1 r 0.704924 0.593556 0.492693 0.840026
p 0.0005* 0.00588 0.0273 <0.0001*
FEV1/FVC ratio r 0.049518 0.169317 0.068836 0.180152 0.126266
p 0.8357 0.475457 0.7730 0.447230 0.5958
MVV r 0.930590 0.923399 0.761158 0.854850 0.766868 0.117326
p <0.0001* <0.0001* <0.0001* <0.0001* <0.0001* 0.6223
FVC: forced vital capacity, FEV1: forced expiratory volume after the ﬁrst second, FEV1/FVC: forced expiratory volume after the ﬁrst second/
forced vital capacity and MVV: maximum voluntary ventilation.
* Signiﬁcant correlation.
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ACQ scoring (Table 4) was signiﬁcantly better (P= 0.0084) in
non-obese than obese patients before treatment (3.860 ± 0.924
vs 4.840 ± 0.728). After receiving treatment for two weeks,both groups had signiﬁcantly improved ACQ scores
(0.660 ± 0.620 vs 2.500 ± 0.577), (P< 0.0001). However,
the improvement (presented by difference between ACQ be-
fore and after treatment (D ACQ)) was signiﬁcantly superior
(P= 0.0031) in non-obese than obese women (3.200 ± 0.670
vs 2.340 ± 0.568).
Figure 4 Scatter diagram showing the signiﬁcant positive correlation found between body fat percentages and circulating concentrations
of OPN in both asthmatics (right) and non asthmatic (left) women.
Figure 5 Scatter diagram showing the signiﬁcant positive correlation found between body fat percentage and serum IgE levels in both
asthmatic (right) and non asthmatic (left) women.
Table 4 Asthma control questionnaire before and after treatment.
Parameters Non-obese asthmatic Obese asthmatic Unpaired t (P1)
ACQ before treatment 3.860 ± 0.924 (2.700–5.100) 4.840 ± 0.728 (3.600–5.700) 2.635102667 P1 = 0.0084
ACQ after treatment 0.660 ± 0.620 (0.000–1.900) 2.500 ± 0.577 (1.400–3.300) 6.865756612 P1 < 0.0001
Paired t (P2) 15.10360261 P2 < 0.0001 13.02683181 P2 < 0.0001
Mean change (D ACQ) 3.200 ± 0.670 (1.800–4.100) 2.340 ± 0.568 (1.500–3.200) 3.096099077 P1 = 0.0031
ACQ: asthma control questionnaire.
P1: Significant difference between obese and non-obese asthmatics by unpaired t test.
P2: Signiﬁcant difference between ACQ before and after treatment in the same group by paired t test.
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correlated to either body fat, serum OPN or IgE, a negative
correlation was detected between D ACQ and the three
parameters (body fat: r= 0.69957; P= 0.0006, serum
OPN: r= 0.68387; P= 0.0009 and IgE concentration:
r= 0.75795; P= 0.0001) (Table 5 and Figs. 7–9).Discussion
Obesity is a determinant of asthma control that is independent
of airway inﬂammation, lung function, and AHR. Asthma in
obese individual tends to be more severe, does not respond well
to treatment and is becoming a major public health issue [27].
Figure 6 Scatter diagram showing the signiﬁcant positive correlation found between serum osteopontin levels and serum IgE levels in
both asthmatic (right) and nonasthmatic (left) women.
Table 5 The correlations between different parameters studied in asthmatic groups.
Parameters studied Body Fat
Percentage
Serum osteopontin
level (lg/l)
Serum IgE levels
(Iu/ml)
ACQ before
treatment
ACQ after
treatment
Serum osteopontin
levels (lg/L)
r 0.92191
p <0.0001*
Serum IgE levels (Iu/
mL)
r 0.83522 0.77018
p <0.0001* <0.0001*
ACQ before
treatment
r 0.42267 0.22555 0.28457
p 0.0633 0.3389 0.2239
ACQ after treatment r 0.83482 0.65496 0.75560 0.74673
p <0.0001* 0.0017* 0.0001* 0.0002*
Mean change (D
ACQ)
r 0.69957 0.68387 0.75795 0.16606 0.53189
p 0.0006* 0.0009* 0.0001* 0.4841 0.0158
ACQ: asthma control questionnaire.
* Signiﬁcant correlation.
The relation between the blood osteopontin levels and body fat percentage 93In the present study, the body fat percentage was signif-
icantly higher in obese asthmatics and non-asthmatics as
compared to non-obese asthmatics and non-asthmatics
while serum OPN levels, the highest values were observed
in the obese asthmatic and the lowest in the non-obese
non-asthmatic patients. Body fat percentage was positively
correlated to serum OPN levels in asthmatic and non-asth-
matic groups.
Gu¨rsoy et al. [28] showed that body fat percentage were
found to be signiﬁcantly higher in obese group than non-obese
group and OPN levels of obese patients were signiﬁcantly
higher than those levels of non-obese controls.
Go´mez-Ambrosi et al. [23] established that obese patients
exhibited a 2-fold increase in plasma OPN concentrations
compared with lean individuals. The signiﬁcant positive corre-
lation between OPN and body fat (assessed by measuring body
fat percentage) seems to indicate that OPN levels are related to
the adipose tissue amount. Again, the increased body fat is
accompanied by high concentrations of OPN in addition to
high levels of some inﬂammatory markers like C-reactive
protein (CRP), TNF-a and ﬁbrinogen, thus reinforcing the
observation that excess adiposity may contribute to the obes-
ity-associated low-grade chronic inﬂammation. Diet-inducedweight loss signiﬁcantly decreased OPN concentrations from
64.7 ± 22.1 to 36.6 ± 20.1 ng/mL.
Increased concentrations of IgE were observed only in the
asthmatic groups but it was signiﬁcantly higher in obese
than non-obese patients. Body fat percentage was positively
correlated to concentrations of IgE in non-asthmatic and in
asthmatic groups. In addition, the correlation between serum
OPN levels and serum IgE levels was signiﬁcantly positive in
non-asthmatics and in asthmatics groups.
Grotta et al. [29] assessed serum IgE levels and eosinophil
counts and found that, they were signiﬁcantly higher in the
asthmatic individuals (obese and non-obese) compared with
the non-asthmatic individuals (obese and non-obese). Circulat-
ing leptin levels were directly correlated with adipose tissue
mass. Leptin is also a proinﬂammatory mediator that enhances
systemic and pulmonary inﬂammation. Therefore, high levels
of leptin are essential in linking obesity to allergic airway
inﬂammation.
Although Fenger et al. [30] explored the association
between adiposity and asthma; they found that all adiposity
measurements were associated with a higher prevalence of
asthma but only among non-atopic individuals. OPN enters
mast cell biology and the regulation of IgE-dependent immune
Figure 7 Scatter diagram showing the signiﬁcant negative correlation found between body fat percentage and mean change in ACQ (D
ACQ) in asthmatic patients.
Figure 8 Scatter diagram showing the signiﬁcant negative correlation found between serum osteopontin levels and mean change in ACQ
(D ACQ) in asthmatic patients.
Figure 9 Scatter diagram showing the signiﬁcant negative correlation found between serum IgE levels and mean change in ACQ (D
ACQ) in asthmatic patients.
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The relation between the blood osteopontin levels and body fat percentage 95responses since it is, reported that connective tissue-type mast
cells from fetal murine skin constitutively secrete biologically
active OPN. Moreover, it is shown that, in vitro, OPN aug-
ments IgE-mediated mast cell degranulation and migration
via ligand binding to cognate OPN receptors on the mast cell
surface (CD44, alpha vs integrin) and that the magnitude of an
IgE-mediated passive cutaneous anaphylaxis reaction is aug-
mented by OPN in vivo [31].
A previous study by Samitas et al. [19] who measured OPN
levels in the serum, bronchoalveolar lavage ﬂuid (BALF) and
bronchial tissue of healthy controls and asthmatics identiﬁed
cellular sources of OPN and examined possible correlations
between OPN expression, disease severity and airway remodel-
ing. Serum samples were obtained from 35 mild-to-moderate
asthmatics, 19 severe asthmatics and 17 healthy controls in
the steady state and in cases of exacerbation. Of these subjects,
29 asthmatics and 9 controls underwent bronchoscopy with
endobronchial biopsy and BALF collection. Reticular base-
ment membrane thickness and goblet cell hyperplasia were
also determined. Serum and BALF OPN levels were signiﬁ-
cantly increased in all asthmatics in the steady state, whereas
serum levels decreased during exacerbations. OPN was upreg-
ulated in the bronchial tissue of all patients, and expressed by
epithelial, airway and vascular smooth muscle cells, myoﬁbro-
blasts, T-lymphocytes and mast cells. OPN expression corre-
lated with reticular basement membrane thickness and was
more prominent in subepithelial inﬂammatory cells in severe
compared to mild-to-moderate asthma. OPN expression is
upregulated in human asthma and associated with remodeling
changes, and its subepithelial expression correlates with dis-
ease severity.
The spirometric results in non-asthmatic women showed
that the percentage of predicted of FVC, FEV1 and MVV were
signiﬁcantly higher in the healthy non obese-non asthmatic
women as compared to the obese non-asthmatic women. How-
ever, FEV1/FVC ratio showed no statistical signiﬁcant differ-
ence between the two groups. These ﬁndings indicate that
obesity has some restrictive effect on pulmonary functions. A
signiﬁcant negative correlation was found between the body
fat percentage and the percentage of predicted of FVC,
FEV1 and MVV’ Furthermore, the percentage of predicted
of FVC, FEV1 and MVV were negatively correlated to serum
OPN levels.
Airﬂow obstruction, as measured by the FEV1/FVC ratio,
is not usually associated with obesity. Indeed, the FEV1/FVC
ratio may be increased in obese individuals if airway closure
and gas trapping reduces the FVC. Because of breathing at
lower functional residual capacity (FRC), airway caliber is de-
creased throughout the tidal breathing cycle, resulting in an in-
crease in airway resistance. Some studies have suggested that
the increase in airﬂow resistance may not be due entirely to
the reduced lung volume, but the cause of the additional resis-
tance remains unknown [32,33].
Salome et al. [34] observed that, obese and non-obese sub-
jects without asthma had similar changes in the percentage of
predicted of FEV1 following methacholine-induced airway
narrowing, but the severity of dyspnea was greater in the obese
group. This difference in symptoms was attributed to a greater
change in the respiratory system reactance in the obese, reﬂect-
ing increased elastic loads. The occurrence of additional elastic
loads in the obese during bronchoconstriction, which are not
well reﬂected by spirometry, may explain why some obeseindividuals with asthma have more severe symptoms than their
lean counterparts despite similar spirometry.
Recent literatures suggest that asthma is different in obese
from non-obese patient. Obesity not only affects lung mechan-
ics, but also has signiﬁcant effects on asthma control and
response to medication, and these changes appear to be inde-
pendent of airway cellular inﬂammation. These differences
may justify adding a new phenotype, ‘‘obesity-associated asth-
ma,’’ to the existing list that includes allergic, occupational,
exercise-induced, nocturnal, aspirin-sensitive, and severe asth-
ma [27,29,30].
ACQ scoring in asthmatic women was signiﬁcantly better in
non-obese than obese patients before treatment. After receiv-
ing treatment for two weeks, both groups had signiﬁcantly im-
proved ACQ scores. However, the improvement (presented by
difference between ACQ before and after treatment (D ACQ))
was signiﬁcantly superior in non-obese women. A negative cor-
relation was detected between D ACQ and the three parame-
ters body fat percentage, serum OPN and IgE concentration.
Although there is a plethora of asthma symptoms question-
naires, ACQ is the ﬁrst to be speciﬁcally developed and
validated to measure asthma control. The ACQ is needed for
research studies to measure the primary goal of asthma treat-
ment, to identify populations at risk and to facilitate compar-
ison of results across studies [25]. ACQ can be used in different
settings by both patients and care providers to assess current
asthma control. Assessment of asthma control by the ACQ;
is inﬂuenced by the type of administration. Honkoop et al.
[35] suggested that better control of asthma is perceived when
interacting with a caregiver than by online self-assessment.
Obesity may worsen asthma via speciﬁc pathophysiologic
mechanisms, such as airway inﬂammation, remodeling and
bronchial hyperresponsiveness, or by the mechanical effects
of obesity on airway function, or there could be other explana-
tions. For example, obesity related co morbidities, such as gas-
troesophageal reﬂux or sleep disordered breathing, could
interact with asthma to increase respiratory dysfunction. In
addition, it is known that obese patients tend to experience
wheezing and breathlessness due to their excess weight. There-
fore, obese patients may have falsely attributed weight related
respiratory symptoms to asthma, causing increased use of their
bronchodilator. Asthma and obesity exhibit a well-established
relationship with evidence pointing toward a more severe and
difﬁcult-to-control obese-asthma phenotype that has altered
responses to controller medications. This phenotype is more
likely to have a worse quality of life, more daily symptoms,
and more exacerbations as well as use more rescue medications
[36].
Obesity has a signiﬁcant adverse effect on asthma control.
Taylor et al. [37] showed that obese individuals with asthma
had more severe symptoms and increased medication use in
multivariate regression adjusted for age, sex, race, income,
and education status. Vortmann and Eisner [38] also found
that obese subjects with asthma who were recruited following
hospital discharge had increased symptoms and decreased
asthma-speciﬁc quality of life when controlling for age, sex,
race, income, and educational status, but did not ﬁnd increased
emergency health care utilization.
In a cross sectional survey study, Mosen et al. [39] showed
that obesity has signiﬁcant adverse effects on symptoms,
medication use, and quality of life, and that, in addition, obese
individuals with asthma have a 4.6-fold increased risk of
96 E.E. Mohamed et al.hospitalization for asthma compared with non-obese individu-
als with asthma in multivariate analysis. The ﬁnding of
increased hospitalizations in the obese by Mosen et al. con-
trasts with the ﬁnding of similar emergency health care utiliza-
tion by Vortmann and Eisner. This may be related to the
different patient populations; all participants in the study by
Vortmann and Eisner had severe asthma and were recruited
following a hospitalization for asthma, whereas Mosen et al.
included individuals with asthma of all disease severities.
Therefore, identifying strategies to improve asthma control
in the obese should be a research priority in this ﬁeld.
Obese patients do not respond as well as normal-weight
individuals to inhaled corticosteroids or inhaled corticoste-
roid/long-acting bronchodilator combination medications.
The explanation for this altered response to asthma controller
therapy is likely to be more complicated than a difﬁculty with
inhaled drug delivery or differences in airway mechanics. Suth-
erland et al. [40] reported that obesity was associated
with attenuated in vitro response to glucocorticoids in a
well-characterized adult group of individuals with moderate
to severe asthma.
In conclusion, this study provided the ﬁrst evidence that
osteopontin is a novel link between obesity and bronchial asth-
ma. Again, it showed a signiﬁcant negative correlation between
asthma improvement and body fat percentage, serum OPN
and IgE concentration. In addition, there was a signiﬁcant
positive correlation between OPN and body fat percentage.
Therefore, multiple roles of OPN action potentially contribute
to inﬂammation in obesity. In this context, it is suggested that,
in addition to weight reduction, interference with OPN action
could become a therapeutic strategy in the treatment of obes-
ity-associated and obesity worsening disorders like bronchial
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